CVE-2024-41668
Published: 23 July 2024
Summary
CVE-2024-41668 is a high-severity SSRF (CWE-918) vulnerability in Wizlynxgroup (inferred from references). Its CVSS base score is 8.3 (High).
Operationally, ranked at the 29.4th percentile by exploit likelihood (below the median); it is not currently listed in the CISA KEV catalog.
EU & UK References
- 🇪🇺 ENISA EUVD: EUVD-2024-39122
Vulnerability details
The cBioPortal for Cancer Genomics provides visualization, analysis, and download of large-scale cancer genomics data sets. When running a publicly exposed proxy endpoint without authentication, cBioPortal could allow someone to perform a Server Side Request Forgery (SSRF) attack. Logged in…
more
users could do the same on private instances. A fix has been released in version 6.0.12. As a workaround, one might be able to disable `/proxy` endpoint entirely via, for example, nginx.
- CWE(s)
Related Threats
No named actor attribution yet. ATT&CK technique mapping in progress for this CVE.
Affected Assets
Mitigating Controls
Likely Mitigating Controls AI
Per-CVE control mapping for this CVE has not run yet; the list below is derived from the weakness types (CWEs) cited in the NVD entry.
Penetration testing attempts server-side requests to internal resources, identifying SSRF weaknesses for remediation.
Outbound connections to external resources can be monitored and limited at the boundary, reducing SSRF impact.
Validates server-side URLs and resource references to block SSRF attempts.
Detects server-side request forgery through monitoring of unexpected outbound connections.